Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Coherus Bio (NQ: CHRS )

1.060 +0.069 (+6.97%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,844,573
Open 1.010
Bid (Size) 1.030 (50)
Ask (Size) 1.080 (335)
Prev. Close 0.9909
Today's Range 0.9840 - 1.090
52wk Range 0.9735 - 4.140
Shares Outstanding 115,208,583
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CHRS Stock Earnings: Coherus BioSciences Beats EPS, Beats Revenue for Q2 2024
CHRS stock results show that Coherus BioSciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
From Coherus BioSciences, Inc.
Via GlobeNewswire

Performance

YTD
-66.24%
-66.24%
1 Month
-26.90%
-26.90%
3 Month
-36.14%
-36.14%
6 Month
-56.20%
-56.20%
1 Year
-73.37%
-73.37%

More News

Read More
Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
From Coherus BioSciences, Inc.
Via GlobeNewswire
Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary
Via Talk Markets
Recap: Coherus BioSciences Q4 Earnings
Via Benzinga
Earnings Preview For Coherus BioSciences
Via Benzinga
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
From Coherus BioSciences, Inc.
Via GlobeNewswire
CHRS Stock Earnings: Coherus BioSciences Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
From Coherus BioSciences, Inc.
Via GlobeNewswire
Why Coherus Biosciences Stock Tumbled on Thursday
Via The Motley Fool
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
From Coherus BioSciences, Inc.
Via GlobeNewswire
Earnings Scheduled For March 13, 2024
Via Benzinga
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Completes Divestiture of Ophthalmology Franchise
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Announces New Employment Inducement Grants
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
From Coherus BioSciences, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.